BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26068980)

  • 1. Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?
    Vassella E; Langsch S; Dettmer MS; Schlup C; Neuenschwander M; Frattini M; Gugger M; Schäfer SC
    Oncotarget; 2015 Sep; 6(27):23905-16. PubMed ID: 26068980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population.
    Tochigi N; Dacic S; Nikiforova M; Cieply KM; Yousem SA
    Am J Clin Pathol; 2011 May; 135(5):783-9. PubMed ID: 21502435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.
    Kang SM; Kang HJ; Shin JH; Kim H; Shin DH; Kim SK; Kim JH; Chung KY; Kim SK; Chang J
    Cancer; 2007 Feb; 109(3):581-7. PubMed ID: 17186532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.
    Shu C; Cheng H; Wang A; Mansukhani MM; Powell CA; Halmos B; Borczuk AC
    Mod Pathol; 2013 Feb; 26(2):239-46. PubMed ID: 22996376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
    J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma].
    Hou LK; Zhang LP; Zhang W; Huang Y; Wu W; Dong ZW; Wu CY
    Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):298-302. PubMed ID: 28468033
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
    Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.
    Shi X; Wu H; Lu J; Duan H; Liu X; Liang Z
    Sci Rep; 2016 Feb; 6():22297. PubMed ID: 26923333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.
    Tseng LH; De Marchi F; Pallavajjalla A; Rodriguez E; Xian R; Belchis D; Gocke CD; Eshleman JR; Illei P; Lin MT
    Am J Clin Pathol; 2019 Oct; 152(5):570-581. PubMed ID: 31264684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
    Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
    Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
    Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays.
    Kenmotsu H; Serizawa M; Koh Y; Isaka M; Takahashi T; Taira T; Ono A; Maniwa T; Takahashi S; Mori K; Endo M; Abe M; Hayashi I; Nakajima T; Ohde Y; Yamamoto N
    BMC Cancer; 2014 Oct; 14():786. PubMed ID: 25348872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
    Zheng R; Shen Q; Mardekian S; Solomides C; Wang ZX; Evans NR
    J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.
    Jia XL; Chen G
    Lung Cancer; 2011 Dec; 74(3):396-400. PubMed ID: 21592614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
    Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.